Taho Pharmaceuticals (ROCO:6467) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6467 Taho Pharmaceuticals Ltd ROCO:6467
34 GF Score
Price NT$135.00
! 2 Warning Signs
View Full Analysis

What is Taho Pharmaceuticals Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ROCO:6467
34GF Score
Taho Pharmaceuticals Ltd ROCO:6467
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Taho Pharmaceuticals Business Description

Address No. 550, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN
Taho Pharmaceuticals Ltd is a Taiwan based company focused on identifying and developing new products that offer therapeutic options to patient populations that may be under served. It offers a transdermal delivery platform that allows the active ingredient to be absorbed by the skin and distributed through the bloodstream. Its transmucosal delivery system delivers the drug as a thin film, an evolution from tablets or capsules. The company is conducting research and development of multiple new drugs using two different drug delivery platform technologies: transdermal and transmucosal.
34GF Score

Get the complete analysis for ROCO:6467

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$135.00
Price